| Title: |
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. |
| Authors: |
Brandi, Maria Luisa, Jan de Beur, Suzanne, Briot, Karine, Carpenter, Thomas, Cheong, Hae Il, Cohen-Solal, Martine, Crowley, Rachel K., Eastell, Richard, Imanishi, Yasuo, Imel, Erik A., Ing, Steven W., Insogna, Karl, Ito, Nobuaki, Javaid, Kassim, Kamenicky, Peter, Keen, Richard, Kubota, Takuo, Lachmann, Robin H., Perwad, Farzana, Pitukcheewanont, Pisit |
| Source: |
Calcified Tissue International; Oct2022, Vol. 111 Issue 4, p409-418, 10p |
| Subject Terms: |
THERAPEUTIC use of monoclonal antibodies, RESEARCH, PAIN, CLINICAL trials, RESEARCH methodology, EVALUATION research, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, BRIEF Pain Inventory |
| Abstract: |
The anti-fibroblast growth factor 23 monoclonal antibody burosumab corrects hypophosphatemia in adults with X-linked hypophosphatemia (XLH) and improves pain, stiffness, physical function, and fatigue. This post hoc subgroup analysis used data from the 24-week placebo-controlled period of a phase 3 study in 134 adults with XLH (ClinicalTrials.gov NCT02526160), to assess whether the benefits of burosumab are evident in 14 clinically relevant subgroups defined by baseline demographic and functional criteria, including sex, Brief Pain Inventory-short form (BPI-SF) Average And Worst Pain, region, race, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) Stiffness, Physical Function and Pain domains and total score, use of opioid/other pain medication, active fractures/pseudo-fractures, and 6-min walk test distance. There were no statistically significant interactions between any of the subgroups and treatment arm for any endpoint. Higher proportions of subjects achieved mean serum phosphate concentration above the lower limit of normal (the primary endpoint) with burosumab than with placebo in all subgroups. For the key secondary endpoints (WOMAC Stiffness and Physical Function; BPI-SF Worst Pain) individual subgroup categories showed improvements with burosumab relative to placebo. For additional efficacy endpoints, burosumab was favored in some subgroups but differences were not significant and confidence intervals were wide. For some endpoints the treatment effect is small at 24 weeks in all subjects. This subgroup analysis shows that burosumab was largely superior to placebo across endpoints in the 14 clinically relevant subgroup variables at 24 weeks and is likely to benefit all symptomatic adults with active XLH. [ABSTRACT FROM AUTHOR] |
|
Copyright of Calcified Tissue International is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
